 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ:XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that data from the ongoing Phase 1 dose-escalation study of vibecotamab XmAb14045, a CD123 x CD3 bispecific antibody, in patients with relapsedrefractory acute myeloid leukemia AML will be presented in an oral session at the 2020 American Society of Hematology ASH Annual M 